Enclomiphene Citrate Compounding Legal Status

Why Enclomiphene Citrate Has No FDA-Approved Label

Enclomiphene citrate is the trans-isomer of clomiphene citrate, isolated from the racemic mixture that has been sold as Clomid since 1967. Despite years of clinical development, no manufacturer has secured FDA approval for enclomiphene as a standalone product.

Repros Therapeutics developed enclomiphene under the brand name Androxal for the treatment of secondary hypogonadism in men. The company submitted a New Drug Application (NDA) to the FDA, but the agency issued a Complete Response Letter in 2015, citing concerns about trial design, endpoint selection, and the need for additional data on long-term cardiovascular outcomes. Repros was later acquired by Allergan, and development of Androxal stalled. No subsequent sponsor has advanced a new NDA for enclomiphene as of May 2026.

Because no approved label exists, the drug cannot be prescribed through conventional pharmacies. This single regulatory fact is what pushes all current enclomiphene prescribing into the compounding space. The FDA's Drugs@FDA database confirms no active NDA or ANDA for enclomiphene citrate.

The Legal Basis for Compounding Enclomiphene

Compounding pharmacies operate under two distinct legal frameworks within the Federal Food, Drug, and Cosmetic Act (FD&C Act). Section 503A governs traditional compounding pharmacies. Section 503B governs outsourcing facilities. Both pathways allow preparation of drugs that are not commercially available, provided specific conditions are met.

Under Section 503A, a compounding pharmacy may prepare enclomiphene citrate for an individual patient with a valid prescription from a licensed prescriber. The pharmacy must comply with state pharmacy board regulations, use bulk drug substances that meet United States Pharmacopeia (USP) standards or appear on the FDA's list of acceptable substances, and refrain from producing copies of commercially available drugs. Since no FDA-approved enclomiphene product exists on the market, this last criterion is satisfied by default.

Under Section 503B, outsourcing facilities registered with the FDA may compound enclomiphene without patient-specific prescriptions and distribute it in larger quantities, including to healthcare facilities. These facilities face more rigorous oversight: they must comply with Current Good Manufacturing Practice (CGMP) requirements, report adverse events to the FDA's MedWatch system, and submit to regular FDA inspections [1].

The distinction matters for patients. A 503B outsourcing facility offers batch-level quality testing that a traditional 503A pharmacy may not provide. Potency and sterility assurance tend to be stronger at inspected 503B facilities, though both pathways are legal when properly followed.

FDA Bulk Drug Substance Evaluation and Its Impact

The FDA maintains a list of bulk drug substances that may be used in compounding, and it periodically evaluates whether specific substances should be added or removed. Enclomiphene citrate has been nominated for inclusion on this list, and the FDA has reviewed it under the agency's bulks evaluation process.

This evaluation considers four criteria: (1) the substance's physical and chemical characterization, (2) safety data, (3) historical use in compounding, and (4) whether a commercially available alternative exists. Enclomiphene scores well on characterization and historical use, given its relationship to approved clomiphene. The safety record, while promising in Phase III trials, lacks the post-marketing surveillance data that an approved product would generate. No commercially equivalent product exists, which supports continued compounding eligibility.

If the FDA were to take negative action on enclomiphene's bulk substance status, compounding pharmacies would lose the legal basis for preparing the drug. This has happened with other substances. The agency removed several bulk drug substances from compounding eligibility between 2018 and 2024 after concluding that safety data were insufficient. Prescribers and patients should monitor the FDA's compounding policy page for updates.

How Enclomiphene Differs from Clomiphene (Clomid) Pharmacologically

Understanding this distinction clarifies why the regulatory paths diverged. Clomiphene citrate (Clomid) is a racemic mixture containing approximately 62% enclomiphene (trans-isomer) and 38% zuclomiphene (cis-isomer). Both isomers act as selective estrogen receptor modulators, but their pharmacokinetic and pharmacodynamic profiles differ substantially.

Enclomiphene has a half-life of roughly 10 hours and acts primarily as an estrogen receptor antagonist at the hypothalamus. It blocks negative feedback from estradiol, which increases GnRH pulsatility, stimulates LH and FSH release, and raises endogenous testosterone production. This is the therapeutically desired effect in men with secondary hypogonadism.

Zuclomiphene, by contrast, has a much longer half-life (approximately 30 days) and accumulates with repeated dosing. It exerts mixed agonist-antagonist effects, contributing to the estrogenic side effects that some men experience on Clomid, including visual disturbances, mood changes, and gynecomastia [2]. A study by Kim et al. in BJU International (2016) found that enclomiphene raised testosterone levels comparably to clomiphene but with a more favorable side-effect profile, specifically fewer visual symptoms and less estrogenic stimulation [3].

This pharmacological rationale drove the original NDA submission. The argument was straightforward: isolate the beneficial isomer, discard the one causing problems. The FDA did not dispute the pharmacology but required stronger efficacy and safety data than the sponsor provided.

Clinical Evidence Supporting Enclomiphene Use

Several Phase II and Phase III trials evaluated enclomiphene in men with secondary hypogonadism, defined as low testosterone (total T <300 ng/dL) with inappropriately normal or low LH and FSH levels. The ZA-301 and ZA-302 trials enrolled over 800 men and tested enclomiphene at 12.5 mg and 25 mg daily doses against topical testosterone gel and placebo.

Results showed that enclomiphene 25 mg raised mean total testosterone into the normal range (average increase to approximately 450 ng/dL from baseline values around 220 ng/dL) while preserving or improving sperm parameters. Topical testosterone, by contrast, suppressed spermatogenesis in most subjects, a finding consistent with the known hypothalamic-pituitary suppression caused by exogenous androgens [4].

The Endocrine Society's 2018 clinical practice guidelines for testosterone therapy in men with hypogonadism do not specifically recommend enclomiphene, as the drug lacks FDA approval. The guidelines do acknowledge off-label use of clomiphene citrate for men who wish to preserve fertility while treating low testosterone, and many clinicians extrapolate this rationale to enclomiphene.

A 2022 retrospective cohort analysis published in the Journal of Urology examined 172 men treated with compounded enclomiphene 25 mg daily for secondary hypogonadism over 12 months. Mean total testosterone increased from 247 ng/dL to 468 ng/dL. Semen parameters were maintained in 94% of subjects. Three patients (1.7%) discontinued due to headache, and one developed a transient visual disturbance that resolved after stopping the drug [5].

Safety Considerations and Known Risks

The safety profile of enclomiphene citrate draws from three sources: the Phase III trial database, post-marketing reports on racemic clomiphene (a reasonable analogue given shared pharmacology), and emerging real-world data from compounding pharmacy adverse-event reports.

Common side effects reported in clinical trials include headache (8.2%), hot flashes (3.1%), and upper respiratory tract infection (2.9%). Serious adverse events were rare. No myocardial infarctions, strokes, or venous thromboembolic events were attributed to enclomiphene in the ZA-301 or ZA-302 trials, though these trials were not powered to detect low-frequency cardiovascular events [3].

The FDA's concern about cardiovascular safety is rooted in broader questions about testosterone-raising therapies. The TTrials (Testosterone Trials) and later the TRAVERSE trial (N=5,246) examined cardiovascular outcomes in men receiving exogenous testosterone. TRAVERSE found no increased incidence of major adverse cardiovascular events (MACE) with testosterone gel versus placebo over a median follow-up of 33 months. Whether these findings apply to endogenous testosterone elevation via SERMs remains an open question, as the mechanism of action differs.

Visual disturbances deserve specific attention. Racemic clomiphene carries an FDA-labeled warning for visual symptoms, including blurred vision, scotomata, and phosphenes, occurring in approximately 1.5% of users. These effects are primarily attributed to the zuclomiphene isomer. Clinical trials of isolated enclomiphene reported visual symptoms at rates below 1%, consistent with removal of the offending isomer [2].

Compounded drug quality is a separate safety variable. The FDA has documented cases of compounding pharmacies producing drugs with incorrect potency, microbial contamination, or degraded active ingredients. Patients filling compounded enclomiphene should verify that their pharmacy holds 503B registration or state board accreditation with a clean inspection history.

State-by-State Variation in Compounding Regulation

Federal law sets the floor for compounding regulation, but states retain authority to impose additional requirements. Some states restrict which substances may be compounded, require additional testing, or limit advertising by compounding pharmacies. This creates variation in enclomiphene availability depending on where a patient lives.

As of early 2026, no state has specifically banned enclomiphene compounding. Several states, including California, Texas, and Florida, have large numbers of 503A and 503B pharmacies actively compounding the drug. States with smaller pharmacy sectors may have fewer options, which can affect pricing and turnaround time.

Patients using telehealth services for enclomiphene prescriptions should confirm that their prescriber is licensed in the state where the patient resides and that the compounding pharmacy is authorized to ship to that state. Interstate compounding by 503B outsourcing facilities is permitted under federal law, but 503A pharmacies face more restrictions on crossing state lines [1].

What Could Change: Scenarios for Regulatory Shift

Three plausible regulatory developments could alter enclomiphene's compounding status.

Scenario 1: A new NDA is filed and approved. If a manufacturer secures FDA approval for enclomiphene, the drug would become commercially available, and 503A pharmacies would likely lose the right to compound it (since it would no longer qualify as "not commercially available"). 503B facilities might retain limited compounding rights for shortage situations. This scenario would increase quality assurance but could also raise costs significantly. No active NDA is in FDA review as of May 2026.

Scenario 2: FDA removes enclomiphene from the bulk substance list. The FDA could conclude that safety data are insufficient to support continued compounding. This would effectively end legal access. The timeline for such action is unpredictable, but the FDA's bulk substance reviews typically span 12 to 24 months from nomination to final decision.

Scenario 3: Status quo continues. Enclomiphene remains available through compounding pharmacies without further regulatory action. This has been the case for several years and is the most likely near-term outcome.

Prescribers should document their clinical rationale for using compounded enclomiphene, including why racemic clomiphene or exogenous testosterone is not appropriate for a given patient. This documentation supports the individualized-need requirement under 503A and provides medicolegal protection if compounding regulations tighten.

How to Verify Your Pharmacy's Compliance

Patients can take specific steps to confirm that their compounded enclomiphene comes from a legitimate source. For 503B outsourcing facilities, the FDA maintains a public registry of registered facilities. Patients should search this list and check whether the facility has any recent warning letters or recalls.

For 503A pharmacies, verification runs through the relevant state board of pharmacy. Most state boards maintain online databases of licensed pharmacies, including inspection results and disciplinary actions. The National Association of Boards of Pharmacy (NABP) offers a lookup tool, and pharmacies with PCAB (Pharmacy Compounding Accreditation Board) accreditation have undergone voluntary third-party review.

Patients should ask their pharmacy whether it performs potency testing on each batch of enclomiphene and whether certificates of analysis are available upon request. A pharmacy that cannot or will not provide this documentation is a red flag. The compounded enclomiphene capsule should contain 12.5 mg or 25 mg of enclomiphene citrate per capsule with a potency within plus or minus 10% of the labeled amount, per USP standards.